SEC Form 4 · accession 0001193125-26-394398
BioStem Technologies, Inc. · BSEM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jason Matuszewski
Officer — Chief Executive Officer · Director · 10% Owner
Period of report
Sep 15, 2026
Accepted (ET)
Sep 17, 2026 · 4:30 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001658678
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 15, 2026 | M | 8,469 | $0.00 | A | 1,286,902 | D | |
| Common Stock | Sep 17, 2026 | M | 16,650 | $0.00 | A | 1,303,552 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF5,F6 | — | Sep 15, 2026 | M | 8,469 | D | — | — | Common Stock | 8,469 | 33,874 | D |
| Restricted Stock UnitsF5,F7 | — | Sep 17, 2026 | M | 16,650 | D | — | — | Common Stock | 16,650 | 99,900 | D |
| Options (Right to Buy)F1 | $2.00 | holding | — | — | — | — | Oct 24, 2032 | Common Stock | 2,250,000 | 2,250,000 | D |
| Options (Right to Buy)F2 | $10.05 | holding | — | — | — | — | Mar 17, 2035 | Common Stock | 198,807 | 198,807 | D |
| Options (Right to Buy)F3 | $10.05 | holding | — | — | — | — | Oct 13, 2035 | Common Stock | 40,427 | 40,427 | D |
| Options (Right to Buy)F4 | $5.50 | holding | — | — | — | — | Feb 11, 2036 | Common Stock | 440,529 | 440,529 | D |
| Restricted Stock UnitsF5,F8 | — | holding | — | — | — | — | — | Common Stock | 363,636 | 363,636 | D |
Explanation of responses
- F1These options are fully vested and exercisable.
- F2These options vest according to the following schedule: 33% vested on March 17, 2026, the one-year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period.
- F3These options vest according to the following schedule: 33%% will vest on October 13, 2026, the one-year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period.
- F4These options vest according to the following schedule: 33% will vest on February 11, 2027, the one year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period.
- F5Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
- F6These restricted stock units vest quarterly over three years from the grant date (September 15, 2024).
- F7These restricted stock units vest according to the following schedule: 33% vested on March 17, 2026, the one year anniversary of the grant date, with the remaining units vesting in equal quarterly installments over the subsequent two year period.
- F8These restricted stock units vest according to the following schedule: 33% will vest on February 11, 2027, the one year anniversary of the grant date, with the remaining units vesting in equal quarterly installments over the subsequent two year period.
Remarks
Exhibit 24 - Power of Attorney